YGEN.L Regulatory News (YGEN)

Premaitha Health plc

Reissue of Options

Manchester, UK - 29 April 2015: Premaitha Health plc ("Premaitha" or "the Company"; AIM: NIPT) announces that, further to the announcement made on 2 October 2014 relating to the grant of options, due to an administrative oversight, options issued under the Company's EMI scheme were not registered with HMRC within the requisite deadline and the split of options announced was reported incorrectly. These options have therefore been cancelled and reissued.

Following the cancellation and reissue of options, the total number of options in issue remains unchanged at 27,963,796 and is as follows:

Vesting conditions of options issued under the Company's EMI and unapproved schemes remain unchanged, such that (i) options only vest if there is a positive movement in earnings per share; (ii) options become exercisable in respect of one third of the ordinary shares over which they are granted on the first, second and third anniversaries of the original date of grant; and (iii) options are exercisable at a price of 10 pence per share.

The issued share capital of the Company is 188,163,709 ordinary shares of 10 pence each.

About Premaitha Health

Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha's flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.

The IONA® test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha's clinical laboratory customers to perform the test in their own facilities. This supports Premaitha's strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.

Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK. For further information please visit www.premaitha.com or email iona@premaitha.com.